Company: CERO
Filing Date: 2025-02-07
Form Type: 424B3
Source: 0001213900-25-011071
Chunk: 113

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-02-07
Form: 424B3
Chunk 113
---
 this prospectus, these factors include:

| ● | the commencement, enrollment                                                                                                         
 or results of any planned and future preclinical studies and clinical trials of our product candidates or changes in the development 
 status of our product candidates;                                                                                                    |

<div align='center'>57</div>

| ● | any delay in our regulatory                                                                                                               
 filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory 
 authority’s review of such filings;                                                                                                       |

| ● | adverse results from or                                                                                                              
 delays in preclinical studies and clinical trials of our product candidates, including as a result of clinical holds, safety events, 
 enrollment difficulties, or study protocol amendments;                                                                               |

| ● | our decision to initiate                                                                       
 a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial; |

| ● | adverse regulatory decisions,                                                                      
 including failure to receive regulatory approval of our drug to market for our product candidates; |

| ● | adverse developments concerning 
 our manufacturers;              |

| ● | our inability to obtain                                                                   
 adequate product supply for any approved drug or inability to do so at acceptable prices; |

| ● | our inability to establish 
 collaborations, if needed; |

| ● | our failure to commercialize 
 our product candidates;      |

| ● | additions or departures                    
 of key scientific or management personnel; |

| ● | unanticipated serious safety                           
 concerns related to the use of our product candidates; |

| ● | introduction of new drugs 
 by our competitors;       |

| ● | announcements of significant                                                                          
 acquisitions, strategic partnerships, joint ventures or capital commitments by us or our competitors; |

| ● | any significant change 
 in our management;     |

| ● | our ability to effectively 
 manage our growth;         |

| ● | the size and growth of      
 our initial target markets; |

| ● | actual or anticipated variations 
 in quarterly operating results;  |

| ● | our cash position; |

| ● | our failure to meet the                                                                               
 estimates and projections of the investment community or that we may otherwise provide to the public; |

| ● | the public’s response                                                                                       
 to press releases or other public announcements by us or third parties, including our filings with the SEC; |

| ● | publication of research                                                                                                           
 reports about us or our industry, or microbiome therapies in particular, or positive or negative recommendations or withdrawal of 
 research coverage by securities analysts;                                                                                         |

| ● | guidance, if any,